Clinical Trial: A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional



Official Title: A Study of the Safety and Efficacy of an Intravenous Immunoglobulin (Vigam® Liquid) in Patients With Primary or Secondary Antibody Deficiency.

Brief Summary:

To determine:

  1. The safety of Vigam® Liquid in patients with primary or secondary antibody deficiency (PAD or SAD).
  2. The efficacy of Vigam® Liquid in patients with primary or secondary antibody deficiency.
  3. The half-life of Vigam® Liquid after 4 months of treatment.
  4. The subclass and total gammaglobulin concentrations after each infusion of Vigam® Liquid.